Immatics biotechnologies

Immatics biotechnologies

Combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. Learn more

Launch date
Employees
Market cap
AUD2.0b
Enterprise valuation
AUD1.1b (Public information from Sep 2024)
Company register number HRB 382151 (Stuttgart)
Tübingen Baden-Württemberg (HQ)
Authorizing premium user...